KUALA LUMPUR: The Health Ministry’s Pharmaceutical Services Division has, today, revoked Hovid Bhd’s manufacturing licences.
In its filing with Bursa Malaysia today, Hovid said the National Pharmaceutical Regulatory Department (NPRA) had on Jan 5, 2017 conducted an audit at its laboratory situated at Lot 56442, 7 ½ Miles, Jalan Ipoh/Chemor, 31200 Chemor, Perak and Lot 121, Jalan Tunku Abdul Rahman, 30010 Ipoh, Perak.
The department had ordered Hovid to withdraw its Ternolol 50 film-coated tablets under batch BG04645. The tablets contain active atenolol ingredients prescribed for hypertension treatment.
Hovid then announced a recall for Ternolol manufactured under batch number BG04645, bearing manufacturing date April 2016, for the Malaysian market.
This was because the boxes labelling the tablets as Ternolol 50 on the outer packaging, contained blisters which were labelled as Ternolol Tab 100mg.
The NPRA had advised patients to return the medicine to clinics, pharmacies or health clinics and ask for advice from medical practitioners and undergo examination if necessary.
Following corrective actions as required by the Health Ministry, Hovid said it will invite the NPRA to audit its facilities again by the end of January 2017.
Hovid said the re-issuance of its manufacturing licences will be subjected to the outcome of the audit.